MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
2.220
-0.090 (-3.90%)
Nov 5, 2026, 4:00 PM EST - Market closed
MacroGenics Revenue
MacroGenics had revenue of $32.83M in the quarter ending June 30, 2026, with 377.97% growth. This brings the company's total for the last twelve months to $167.67M, up 11.69% year-over-year. In the year 2025, MacroGenics had annual revenue of $149.50M, down -0.31%. That makes MacroGenics the 18,432nd largest company in the world by revenue and 2,950th in the United States.
Revenue (ttm)
$167.67M
Revenue Growth
+11.69%
P/S Ratio
0.81
Revenue / Employee
$597,754
Employees
293
Market Cap
141.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 149.50M | -462.00K | -0.31% |
| Dec 31, 2024 | 149.96M | 91.21M | 155.26% |
| Dec 31, 2023 | 58.75M | -93.19M | -61.33% |
| Dec 31, 2022 | 151.94M | 74.49M | 96.19% |
| Dec 31, 2021 | 77.45M | -27.44M | -26.16% |
| Dec 31, 2020 | 104.88M | 40.70M | 63.40% |
| Dec 31, 2019 | 64.19M | 4.07M | 6.76% |
| Dec 31, 2018 | 60.12M | -97.62M | -61.89% |
| Dec 31, 2017 | 157.74M | 65.86M | 71.68% |
| Dec 31, 2016 | 91.88M | -8.97M | -8.90% |
| Dec 31, 2015 | 100.85M | 53.06M | 111.00% |
| Dec 31, 2014 | 47.80M | -10.24M | -17.64% |
| Dec 31, 2013 | 58.04M | -5.79M | -9.07% |
| Dec 31, 2012 | 63.83M | 6.62M | 11.57% |
| Dec 31, 2011 | 57.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 45.70M |
| Cue Biopharma | 37.66M |
| Atrium Therapeutics | 35.84M |
| Adagene | 9.29M |
| Compass Therapeutics | 850.00K |
| Veraxa Biotech AG | 29.54K |
MGNX News
- 4 hours ago - MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 days ago - MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D. - GlobeNewsWire
- 10 days ago - MacroGenics announces interim data from LINNET study evaluating lorigerlimab - TheFly
- 10 days ago - MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer - GlobeNewsWire
- 13 days ago - MacroGenics announces interim data from MGC026 study - TheFly
- 13 days ago - MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN - GlobeNewsWire
- 21 days ago - MacroGenics doses first patient in MGC030 study - TheFly
- 21 days ago - MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors - GlobeNewsWire